Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | SLC6A19 | Q695T7 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151323 | 0.84 | HCAR2 (0.56) | GLAHCAR2MMP1MMP2MMP9 | |
| SCHEMBL14233717 | 0.83 | LMNA (0.45) | — | |
| SCHEMBL25852781 | 0.82 | HCAR2 (0.54) | HCAR2MMP1MMP2MMP9MMP12 | |
| SCHEMBL10243039 | 0.82 | LMNA (0.44) | — | |
| SCHEMBL28168490 | 0.81 | HCAR2 (0.56) | GLAHCAR2MMP1MMP2MMP9 | |
| SCHEMBL13735763 | 0.81 | HTT (0.59) | GLAHCAR2MMP1MMP2MMP9 | |
| SCHEMBL27574865 | 0.81 | GLA (0.53) | GLAHCAR2MMP1MMP2MMP9 | |
| SCHEMBL5943754 | 0.81 | GLA (0.56) | GLAHCAR2MMP1MMP2MMP9 | |
| SCHEMBL137308 | 0.80 | LMNA (0.65) | — | |
| SCHEMBL14233691 | 0.79 | SMN1; SMN2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605301-B | Method for preparing Pa Luo Weide intermediate | 江苏恒沛药物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-114605301-A | Method for preparing intermediate of palovir | 江苏恒沛药物科技有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114605301-B | Method for preparing Pa Luo Weide intermediate | 江苏恒沛药物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023184898-A1 | BIFUNCTIONAL COMPOUND FOR SIMULTANEOUSLY REGULATING BTK AND IKZF3 | 水木未来(北京)科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| CN-116462664-A | Pyrazole ring compound, preparation method, composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-115626949-A | BET protein targeted degradation compound and preparation method and application thereof | 南京澳健生物制药有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-114605301-A | Method for preparing intermediate of palovir | 江苏恒沛药物科技有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114409658-B | Bifunctional compound capable of simultaneously regulating BTK and IKZF3 | 水木未来(北京)科技有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114409658-A | Bifunctional compound capable of simultaneously regulating BTK and IKZF3 | 水木未来(北京)科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-111233758-B | PSMA inhibitor, application thereof and nuclear species imaging reagent targeting PSMA | 北京大学第一医院 | 2021-04-23 | — | — | CN | disclosed |
| CN-111233758-A | PSMA inhibitor, application thereof and nuclear species imaging reagent targeting PSMA | 北京大学第一医院 | 2020-06-05 | — | — | CN | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | GLA 141/4885HCAR2 2195/4885MMP1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.